The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Phage Cocktails and the Future of Phage Therapy
Open accessAbstract
Viruses of bacteria, known as bacteriophages or phages, were discovered nearly 100 years ago. Their potential as antibacterial agents was appreciated almost immediately, with the first 'phage therapy' trials predating Fleming's discovery of penicillin by approximately a decade. In this review, we consider phage therapy that can be used for treating bacterial infections in humans, domestic animals and even biocontrol in foods. Following an overview of the topic, we explore the common practice - both experimental and, in certain regions of the world, clinical - of mixing therapeutic phages into cocktails consisting of multiple virus types. We conclude with a discussion of the commercial and medical context of phage cocktails as therapeutic agents. In comparing off-the-shelf versus custom approaches, we consider the merits of a middle ground, which we deem 'modifiable'. Finally, we explore a regulatory framework for such an approach based on an influenza vaccine model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
US Environmental Protection Agency
(1998) · Choice Reviews Online · doi:10.5860/choice.35-4455 · Cited by 5,897
Bacteriophage resistance mechanisms
Labrie, S. J., Samson, J. E., & Moineau, S. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2315 · Cited by 2,397
Bacteriocins—A viable alternative to antibiotics?
Cotter, P. D., Ross, R. P., & Hill, C. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro2937 · Cited by 1,793
Antibiotics for Emerging Pathogens
Fischbach, M. A., & Walsh, C. T. (2009) · Science · doi:10.1126/science.1176667 · Cited by 1,777
(2001) · Wiley eBooks · doi:10.1002/047001590x · Cited by 1,111
Evolutionary relationships among diverse bacteriophages and prophages: All the world’s a phage
Hendrix, R. W., Smith, M. C. M., Burns, R. N., Ford, M. E., & Hatfull, G. F. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2192 · Cited by 1,107
Pros and cons of phage therapy
Loc-Carrillo, C., & Abedon, S. T. (2011) · Bacteriophage · doi:10.4161/bact.1.2.14590 · Cited by 1,020
Self-citationPhage treatment of human infections
Abedon, S. T., Kuhl, S. J., Blasdel, B. G., & Kutter, E. M. (2011) · Bacteriophage · doi:10.4161/bact.1.2.15845 · Cited by 980
Self-citationAN INVESTIGATION ON THE NATURE OF ULTRA-MICROSCOPIC VIRUSES.
Twort, F. W. (1915) · The Lancet · doi:10.1016/s0140-6736(01)20383-3 · Cited by 901
Molecular Biology of Bacteriophage T4
(1994) · ASM Press eBooks · doi:10.1128/ecosalplus.bacteriophage-t4 · Cited by 878
Cited by
Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review
Mulani, M. S., Kamble, E. E., Kumkar, S. N., Tawre, M. S., & Pardesi, K. R. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00539 · Cited by 1,644
Jault, P., Leclerc, T., Jennes, S., Pirnay, J. P., Que, Y.-A., Resch, G., Rousseau, A. F., Ravat, F., Carsin, H., Le Floch, R., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30482-1 · Cited by 874
Resistance Development to Bacteriophages Occurring during Bacteriophage Therapy
Oechslin, F. (2018) · Viruses · doi:10.3390/v10070351 · Cited by 594
Phage on tap–a quick and efficient protocol for the preparation of bacteriophage laboratory stocks
Bonilla, N., Rojas, M. I., Netto Flores Cruz, G., Hung, S.-H., Rohwer, F., & Barr, J. J. (2016) · PeerJ · doi:10.7717/peerj.2261 · Cited by 353
Pires, D., Melo, L., Vilas Boas, D., Sillankorva, S., & Azeredo, J. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.09.004 · Cited by 312
Revisiting phage therapy: new applications for old resources
Nobrega, F. L., Costa, A. R., Kluskens, L. D., & Azeredo, J. (2015) · Trends in Microbiology · doi:10.1016/j.tim.2015.01.006 · Cited by 310
Finding alternatives to antibiotics
Allen, H. K., Trachsel, J., Looft, T., & Casey, T. A. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12468 · Cited by 269
Maciejewska, B., Olszak, T., & Drulis-Kawa, Z. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-8811-1 · Cited by 222
Enhancing phage therapy through synthetic biology and genome engineering
Lenneman, B. R., Fernbach, J., Loessner, M. J., Lu, T. K., & Kilcher, S. (2021) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.11.003 · Cited by 208
High-throughput mapping of the phage resistance landscape in E. coli
Mutalik, V. K., Adler, B. A., Rishi, H. S., Piya, D., Zhong, C., Koskella, B., Kutter, E. M., Calendar, R., Novichkov, P. S., Price, M. N., et al. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000877 · Cited by 171
Kunisch, F., Campobasso, C., Wagemans, J., Yildirim, S., Chan, B. K., Schaudinn, C., Lavigne, R., Turner, P. E., Raschke, M. J., Trampuz, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52595-w · Cited by 101
Self-citationThe genetic basis of phage susceptibility, cross-resistance and host-range in Salmonella
Adler, B. A., Kazakov, A. E., Zhong, C., Liu, H., Kutter, E., Lui, L. M., Nielsen, T. N., Carion, H., Deutschbauer, A. M., Mutalik, V. K., et al. (2021) · Microbiology · doi:10.1099/mic.0.001126 · Cited by 65
Bacteriophage Therapy: Discovery, Development, and FDA Approval Pathways
Niazi, S. K. (2025) · Pharmaceuticals · doi:10.3390/ph18081115 · Cited by 56
Bacteriophages as Targeted Therapeutic Vehicles: Challenges and Opportunities
Venkataraman, S., Shahgolzari, M., Yavari, A., & Hefferon, K. (2025) · Bioengineering · doi:10.3390/bioengineering12050469 · Cited by 38
Mutalik, V. K., & Arkin, A. P. (2022) · iScience · doi:10.1016/j.isci.2022.104121 · Cited by 32
Isolation and characterization of novel Fusobacterium nucleatum bacteriophages
Wang, Y., Liu, Z., Chen, Q., Yi, L., Xu, Z., Cai, M., Qin, J., Zhang, Y., Du, G., Hong, J., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.945315 · Cited by 23
Nanomedicine for phage therapy: Encapsulation strategies for enhanced antimicrobial efficacy
Dorta-Gorrín, A., Salgueiriño, V., & García-Hevia, L. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2025.107660 · Cited by 16
Metadata
- Authors
- Chan, B. K., Abedon, S. T., & Loc-Carrillo, C.
- Venue
- Future Microbiology
- Publisher
- Informa UK Limited
- Published
- 2013-05-23
- Volume
- 8
- Issue
- 6
- Pages
- 769-783
- ISSN
- 1746-0913 (ISSN-L)
- 1746-0921
- OpenAlex
- W2123978130
- Cited by
- 914
- References
- 77
- FWCI
- 37.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.